Results 151 to 160 of about 33,191 (261)

Serum Soluble ST2

Journal of the American College of Cardiology, 2010
Weir, Robin A.P., Miller, Ashley M., Murphy, Grace E.J., Clements, Suzanne, Steedman, Tracey, Connell, John M.C., McInnes, Iain B., Dargie, Henry J., McMurray, John J.V.   +8 more
openaire   +1 more source

Sequence‐Specific Primer Polymerase Chain Reaction Genotyping of the Human IL33 Polymorphism rs1929992 (T > C) with Sanger Sequencing Validation

Current Protocols, Volume 6, Issue 9, September 2026.
Abstract Single‐nucleotide polymorphisms (SNPs) may influence gene expression and contribute to interindividual variability in immune responses and disease susceptibility. Interleukin‐33 (IL33), a cytokine involved in inflammation, immune regulation, epithelial barrier homeostasis, and tissue remodeling, has been implicated in allergic, autoimmune ...
Aléia Harumi Uchibaba Yamanaka, Guilherme Castellani, Matheus Braga, Josiane Bazzo de Alencar, Letícia Cristina de Almeida Silva, Quirino Alves de Lima Neto   +5 more
wiley   +1 more source

Beyond the alarm: unveiling the multifaceted role of IL-33 in kidney disease. [PDF]

Front Immunol
Yang M, Miao S, Yu M, Fu X, Qin X.
europepmc   +1 more source

ST2 promotes TOLerance [PDF]

Nature Reviews Immunology, 2004
openaire   +1 more source

Development of 2‑Methyl-5-phenylpyrrolidine-Based ST2 Inhibitors for Neuroinflammatory Conditions. [PDF]

ACS Med Chem Lett
Yuan X, Cho EB, Patil AD, Aktaruzzaman M, Ramaraju A, Jiang C, Wang M, He M, Robida A, Wen B, Sun D, Rech JC, Jiang J, Yang CY.   +13 more
europepmc   +1 more source

Circulating Tumor DNA and Immune Response Markers for Improved Treatment Outcome Prediction in Diffuse Large B‐Cell Lymphoma: A Scoping Review

Hematological Oncology, Volume 44, Issue 5, September 2026.
ABSTRACT Early identification of refractory disease remains a significant unmet clinical need in patients with diffuse large B‐cell lymphoma (DLBCL). This scoping review was conducted to assess the current knowledge on the use of circulating tumor DNA (ctDNA), either alone or in combination with immune markers, as predictive tools for treatment outcome
Ailin McMahon, Elizabeth J. Ryan, Sarah Dillon, Ruth Clifford   +3 more
wiley   +1 more source

RNAi targeting Myzus persicae (Hemiptera) stylet cuticle proteins reduces ZYMV transmission. [PDF]

Virus Res
Liang J, Ghodke AB, Fletcher SJ, Manzie N, Robinson KE.   +4 more
europepmc   +1 more source

DAMPs, PAMPs, and Alarmins: From Mechanism to Therapy

MedComm, Volume 7, Issue 9, September 2026.
This review synthesizes the expanding biology of PAMPs and DAMPs, from their molecular sources and sensing mechanisms to regulatory networks that govern inflammation and homeostasis. Spanning from classical immune activation to trained immunity and interorgan communication, we highlight the interplay between PAMPs and DAMPs and their context‐dependent ...
Xuanxuan Yu, Yuqin Jin, Baochao Li, Jie Deng, Yiwen Zhou, Jinglun Zhang, Huang Li   +6 more
wiley   +1 more source

P-110 Soluble St2 [PDF]

Inflammatory Bowel Diseases, 2014
Quera Rodrigo, Diaz-Jimenez David, Simian Daniela, De La Fuente Marjorie, Landskron Glauben, Garcia Paulina, Dubois Karen, Fuentes Janitza, Perez Tamara, Hermoso Marcela   +9 more
openaire   +1 more source

Metabolism in Tumor: Mechanisms and Therapeutic Perspectives

MedComm, Volume 7, Issue 9, September 2026.
Tumor metabolic reprogramming converges on three hubs—the SREBP1/2–FASN–SCD1 lipogenic axis, the HIF‐1α–GLUT1–LDHA glycolytic axis, and the LDLR–SCARB1–LXR cholesterol system—which integrate transcriptional, epigenetic (histone lactylation, m6A), and microenvironmental inputs to generate metabolic plasticity, immune evasion, and therapy resistance ...
Jia‐Chen Cheng, Yi‐Xuan Hu, Xiang‐Chun Huang, Shan Jiang, Jie‐Lin Wang, Yang Zhao, Shuo Chen   +6 more
wiley   +1 more source